BrainsWay Ltd. (BWAY) NASDAQ
13.57
-0.01(-0.07%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
13.57
-0.01(-0.07%)
Currency In USD
Sector
Healthcare
Industry
Medical - Devices
Employees
120
First IPO Date
April 17, 2019
| Name | Title | Pay | Year Born |
| Hadar Levy | Chief Executive Officer | 542,495 | 1973 |
| David Zacut | Co-Founder & Vice-Chairman | 40,246 | 1953 |
| Avner Hagai | Founder & Director | 41,989 | 1956 |
| Abraham Zangen | Co-Founder, Member of Scientific Advisory Board & Director | 69,921 | 1970 |
| Yiftach Roth | Founder & Chief Scientific Officer | 108,000 | 1971 |
| Ross Mitchell | Vice President of Global Marketing | 287,492 | N/A |
| Ido Marom | Chief Financial Officer | 303,199 | 1976 |
| Colleen Hanlon | Vice President of Medical Affairs | 327,488 | N/A |
| Michael Cohen | Vice President of US Sales | 397,438 | N/A |
| Dor Hagai | Vice President of Operations | 0 | N/A |
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.